Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
- 1 July 1994
- journal article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 47 (7) , 657-660
- https://doi.org/10.1136/jcp.47.7.657
Abstract
AIMS--To determine the changes in serum zinc concentration and the extent of urinary zinc excretion in patients with iron overload receiving the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) or desferrioxamine (DFX), and to correlate these results with blood glucose concentration. METHODS--Serum zinc and ferritin concentrations, urinary zinc and iron excretion were regularly assayed in 39 patients and the glucose tolerance test (GTT) was performed in each patient. Patients were segregated according to their GTT into normal, diabetic, and those with an abnormal GTT. The mean of L1- or DFX associated urinary zinc excretion for each group was determined and compared with the other two groups and with normal value. L1 associated urinary zinc excretion was also compared with L1 dose, serum ferritin values, and urinary iron excretion. RESULTS--Both DFX and L1 were associated with a significantly increased urinary zinc excretion (15.1 (7.3) mumol/24 hours, 11.1 (6.0) mumol/24 hours, respectively) compared with normal subjects. In patients receiving DFX this increase only occurred in patients with diabetes mellitus. Both diabetic and non-diabetic patients receiving L1 treatment excreted more zinc than normal. Diabetic patients receiving L1 or DFX excreted more zinc than non-diabetics receiving the same treatment. No correlation was found between urinary zinc excretion and L1 dose or patients' serum ferritin concentrations. In seven patients receiving long term L1 treatment a fall in serum zinc was observed from an initial 13.6 (1.6) mumol/l to a final 9.6 (0.8) mumol/l. In one patient this was associated with symptoms of dry skin and itchy skin patches requiring treatment with oral zinc sulphate. CONCLUSIONS--In contrast to DFX, L1 treatment is associated with increased zinc loss. This, however, is modest and does not lead in most patients to subnormal serum zinc concentrations. In a few patients whose negative zinc balance may give rise to symptoms, zinc supplementation rapidly corrects the deficit.Keywords
This publication has 15 references indexed in Scilit:
- Effects of diabetes type and treatment on zinc status in diabetes mellitusBiological Trace Element Research, 1992
- Zinc levels after intravenous administration of zinc sulphate in insulin-dependent diabetes mellitus patientsJournal of Molecular Medicine, 1991
- 65 Zinc absorption in patients with insulin-dependent diabetes mellitus assessed by whole-body counting techniqueClinica Chimica Acta; International Journal of Clinical Chemistry, 1990
- Zinc in kidney disease.Journal of the American College of Nutrition, 1989
- Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA.Archives of Disease in Childhood, 1989
- A serum ferritin assay for prevalence studies of iron deficiencyAmerican Journal of Hematology, 1986
- Iron chelation using subcutaneous infusions of diethylene triamine penta‐acetic acid (DTPA)Scandinavian Journal of Haematology, 1986
- Abnormal zinc metabolism in type II diabetes mellitusThe American Journal of Medicine, 1983
- Zinc, iron, and copper absorption in the streptozotocin-diabetic ratAmerican Journal of Physiology-Endocrinology and Metabolism, 1983
- Serum copper and related variables in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1978